- Home
- SKYE vs LUCD Comparison
SKYE vs LUCD Comparison
Compare SKYE & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- LUCD
- Stock Information
- Founded
- SKYE 2012
- LUCD 2018
- Country
- SKYE United States
- LUCD United States
- Employees
- SKYE N/A
- LUCD N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SKYE Health Care
- LUCD Health Care
- Exchange
- SKYE Nasdaq
- LUCD Nasdaq
- Market Cap
- SKYE 121.8M
- LUCD 108.0M
- IPO Year
- SKYE N/A
- LUCD 2021
- Fundamental
- Price
- SKYE $1.33
- LUCD $1.24
- Analyst Decision
- SKYE Strong Buy
- LUCD Strong Buy
- Analyst Count
- SKYE 5
- LUCD 5
- Target Price
- SKYE $14.75
- LUCD $3.70
- AVG Volume (30 Days)
- SKYE 1.8M
- LUCD 1.3M
- Earning Date
- SKYE 11-06-2025
- LUCD 11-12-2025
- Dividend Yield
- SKYE N/A
- LUCD N/A
- EPS Growth
- SKYE N/A
- LUCD N/A
- EPS
- SKYE N/A
- LUCD N/A
- Revenue
- SKYE N/A
- LUCD $4,360,000.00
- Revenue This Year
- SKYE N/A
- LUCD $13.90
- Revenue Next Year
- SKYE N/A
- LUCD $163.88
- P/E Ratio
- SKYE N/A
- LUCD N/A
- Revenue Growth
- SKYE N/A
- LUCD 14.74
- 52 Week Low
- SKYE $1.14
- LUCD $0.75
- 52 Week High
- SKYE $5.96
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- SKYE 27.04
- LUCD 59.00
- Support Level
- SKYE $1.50
- LUCD $1.17
- Resistance Level
- SKYE $1.76
- LUCD $1.27
- Average True Range (ATR)
- SKYE 0.24
- LUCD 0.07
- MACD
- SKYE -0.15
- LUCD 0.02
- Stochastic Oscillator
- SKYE 0.68
- LUCD 85.19
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.